Funding for this research was provided by:
Pfizer
Article History
Accepted: 19 January 2021
First Online: 26 March 2021
Declarations
:
: This analysis was sponsored by Pfizer.
: S. Riley, M. Boucher, and L.O. Harnisch are full-time employees of, and hold stock and/or stock options with, Pfizer. C. Vong was a full-time employee of Pfizer at the time of the analysis; she is now a full-time employee of Novartis AG and holds stock options with Novartis AG.
: ATTR-ACT was approved by the independent review board or ethics committee at each participating site and was conducted in accordance with the provisions of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines.
: All patients provided written informed consent.
: All authors have given their consent for the publication of this manuscript.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See ExternalRef removed for more information.
: Not applicable.
: All authors contributed to the design of the analysis, data acquisition and interpretation, and to the drafting and revising of the manuscript.